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1ABSTRACT
Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy 
Alone for Advanced Gastric Cancer with Krukenberg Tumor
Jang Ho Cho
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Jae Yong Cho)
This study was conducted to validate the survival benefit of metastasectomy 
plus chemotherapy over chemotherapy alone for treatment of Krukenberg 
tumors from gastric cancer and to identify prognostic factors for survival. 
Clinical data from 216 patients with Krukenberg tumors from gastric cancer 
were collected. Patients were divided into two arms according to treatment 
modality: arm A, metastasectomy plus chemotherapy and arm B, chemotherapy 
alone. Overall survival (OS) was significantly increased in arm A relative to 
arm B for patients initially diagnosed with stage IV gastric cancer (18.0 months 
vs. 8.0 months; p < 0.001) and those with recurrent Krukenberg tumors (19.0 
months vs. 9.0 months; p=0.002), respectively. Metastasectomy (hazard ratio 
[HR], 0.458; 95% confidence interval [CI], 0.287 to 0.732; p=0.001), 
signet-ring cell pathology (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and 
peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were 
significant prognostic factors for survival. Metastasectomy plus chemotherapy 
offers superior OS when compared to palliative chemotherapy alone in gastric 
cancer with Krukenberg tumor. Prolonged survival applies to all patients, 
regardless of gastric cancer stage. Metastasectomy, signet-ring cell pathology, 
2and peritoneal carcinomatosis were prognostic factors for survival. Future 
prospective randomized trials are needed to confirm the optimal treatment 
strategy for Krukenberg tumors from gastric cancer.
----------------------------------------------------------------------------------------
Key words : krukenberg tumor, metastasectomy, prognosis, stomach 
neoplasms
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(Directed by Professor Jae Yong Cho)
I. INTRODUCTION
Gastric cancer is the second leading cause of cancer-related death worldwide. 
In Western countries, the incidence of gastric cancer has been decreasing, 
whereas it remains a main cause of cancer-related death in Korea. Gastric cancer 
infrequently metastasizes to the ovary, a hormone-related organ. The incidence of 
ovarian metastasis or Krukenberg tumor after curative resection of gastric cancer 
is approximately 0.3%-6.7%1,2; however, some autopsy studies have reported 
incidence rates ranging from 33% to 41%1,2. Krukenberg tumor is associated with 
poor prognosis in gastric cancer3,4. In female patients, one of the most important 
causes of treatment failure for gastric cancer is an ovarian relapse5,6. Significant 
advances have been made in understanding the molecular biology of many 
cancers. However, the underlying mechanism of the intratumor heterogeneity of 
gastric cancer has not been clearly established. Furthermore, the prognostic 
factors and treatment guidelines for patients diagnosed with Krukenberg tumor of 
gastric origin are insufficient. Although systemic chemotherapy is the optimal 
treatment strategy for recurrent or metastatic gastric cancer, it has not provided 
4significant survival benefits. Therefore, several treatment strategies have been 
investigated to improve overall survival (OS) in metastatic gastric cancer patients 
with oligometastases or limited metastasis. Several local treatments including 
metastasectomy, radiofrequency ablation, and stereotactic body radiation therapy 
have shown impressive results7,8. Additionally, resection of metastatic lesions has 
been shown to increase OS in colorectal cancer (CRC) patients with operable 
liver and lung metastases9-12. Therefore, National Comprehensive Cancer 
Network guidelines recommend metastasectomy for operable lung and liver 
lesions in CRC. However, the survival benefit of metastasectomy has not been 
clearly validated for Krukenberg tumors in gastric cancer. Most Krukenberg 
tumors are diagnosed metachronously, and only a few patients with Krukenberg 
tumor are clinically diagnosed synchronously. In most hospitals, patients initially 
diagnosed with ovarian metastasis in advanced gastric cancer are primarily 
treated with chemotherapy. However, there is limited clinical data available 
regarding the survival benefit of ovarian metastasectomy in patients with 
advanced gastric cancer13. Moreover, controversies regarding the best treatment 
strategy for Krukenberg tumor in gastric cancer have caused confusion among 
physicians. Therefore, we investigated the survival benefit of ovarian 
metastasectomy in synchronous or metachronous Krukenberg tumor in gastric 
cancer.
II. MATERIALS AND METHODS
1. Patients
Of 27,103 patients who were diagnosed with gastric cancer between March 
2004 and February 2012 at Yonsei University Medical Center, 9,217 (34%) were 
women. Among female gastric cancer patients, 216 with Krukenberg tumor 
detected by abdominal-pelvis computed tomography (CT) or gynecologic 
ultrasonography were included in this study and reviewed retrospectively 
5(Severance Hospital, n=172; Gangnam Severance Hospital, n=44). Patient 
information was obtained from outpatient clinical or admission records and 
information regarding patient survival was obtained from the Korean National 
Statistics Registry Database. The protocols were approved by the Yonsei 
University Health System Institutional Review Board. In general, curative surgery 
plays an important role in gastric cancer without distant metastasis. Therefore, for 
data analysis, patients were divided into two groups according to initial gastric 
cancer stage: stage I-III and stage IV. Patients received surgery or palliative 
chemotherapy according to the initial disease stage. Patients suspected of having 
Krukenberg tumor underwent imaging studies to confirm disease resectability. 
However, 87% of patients (93/107) who underwent oophorectomy had disease that 
already extended beyond the ovary, in which case oophorectomy was performed 
for palliative symptom control. The residual disease state of each patient was 
documented as the presence or absence of gross residual disease, which was 
classified as negative resection margins (R0), microscopic tumor infiltration (R1), 
and macroscopic residual tumor (R2). R0 resection was achieved in only 38% 
(41/107) of patients who underwent oophorectomy. Overall, 125 patients were 
initially diagnosed with stage IV gastric cancer and 91 with recurrent Krukenberg 
tumor after they underwent curative resection of gastric cancer. Among the 
patients initially diagnosed with stage IV gastric cancer, Krukenberg tumors were 
detected synchronously and metachronously in 84 patients and 41 patients, 
respectively. To compare OS, patients with initial stage IV gastric cancer (n=125) 
were divided into two arms according to treatment modality. Arm A1 comprised 
49 patients who received both chemotherapy and metastasectomy for Krukenberg 
tumor. Arm B1 comprised 76 patients who received chemotherapy alone. Patients 
with recurrent Krukenberg tumor (n=91) were assigned to arm A2 or arm B2. Arm 
A2 comprised 58 patients who received chemotherapy and metastasectomy for 
recurrent Krukenberg tumor, and arm B2 comprised 33 patients who received 
chemotherapy alone. In arms A1 and B1, OS was defined as the time from the date 
6of pathologic diagnosis of gastric cancer to the date of death or last followup. In 
arms A2 and B2, OS was defined as the time from the date of Krukenberg tumor 
diagnosis by imaging to the date of death or last follow-up.
2. Statistical analyses
All statistical analyses were performed using IBM SPSS ver. 20.0 (IBM Co., 
Armonk, NY). For continuous variables, two-tailed Student t tests were used to 
compare the demographic and clinical characteristics between patient arms. For 
discrete variables, a chi-square test was used. Survival rates and 95% confidence 
intervals (CIs) were calculated using the Kaplan-Meier method. The influence of 
the covariates on survival length between treatment arms was assessed using the 
log-rank test. A p-value of < 0.05 was considered significant. Significant 
variables in the univariate analysis were entered into multivariate analysis using 
the Cox proportional hazards model.
III. RESULTS
1. Clinical characteristics
The median follow-up duration for all patients was 30.0 months until the OS 
data cutoff date (June 30, 2013), at which time 90% of the patients had 
discontinued treatment. The median age of patients at Krukenberg tumor 
diagnosis was 43.4 years (range, 21 to 78 years) and the average size of 
metastatic ovarian tumors was 6.8 cm (range, 1.5 to 24 cm). The clinical 
characteristics of patients with initial stage IV gastric cancer (n=125) are listed in 
Table 1. Patients were divided into two arms according to treatment modality: 
arm A, metastasectomy plus chemotherapy; arm B, chemotherapy alone. 
Comparison of the patients who received chemotherapy plus metastasectomy 
revealed they had significantly larger Krukenberg tumors (median size, 7.99 cm 
vs. 5.76 cm; p=0.004), fewer metastases outside the ovaries (85.7% vs. 97.4%; 
7p=0.028), and a more normal range of serum cancer antigen (CA) 19-9 level 
(65.3% vs. 39.5%; p=0.009) than patients who received chemotherapy alone. The 
clinical characteristics of patients with recurrent Krukenberg tumor of gastric 
origin (n=91) are listed in Table 2. Patients who received chemotherapy plus 
metastasectomy had significantly higher frequency of bilateral tumors (72.4% vs. 
48.5%; p=0.022), and a more normal range of serum CA 19-9 level (65.6% vs. 
45.5%; p=0.035) than those who received chemotherapy alone.
8Table 1. Clinical Characteristics of 125 Patients with Initial Stage IV
Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus 
chemotherapy and arm B, chemotherapy alone.
*WD-MD, adenocarcinoma, well differentiated and adenocarcinoma, moderate differentiated; PD-SRC, 
adenocarcinoma, poorly differentiated and signet ring cell carcinoma. 
+CEA, carcinoembryonic antigen; CA, cancer antigen
a)Serum CEA>5ng/mL, b)Serum CA-19-9>24U/mL, c)Serum CA 125>35U/mL.
p-values from chi-square test except for krukenberg tumor size, median age at krukenberg tumor diagnosis 
(Two-tailed Student’s t-test).
Variables Arm A1#(n=49) Arm B1#(n=76) p value
Median age (yr) 43.3 (26-69) 42.1 (27-72) 0.428
< 50 39 (80.0%) 64 (84.2%)
0.508
≥50 10 (20.4%) 12 (15.8%)
Laterality
0.315Bilateral 37 (75.5%) 51 (67.0%)
Unilateral 12 (24.5%) 25 (33.0%)
Krukenberg tumor size (cm) 7.99 (3.4-19) 5.76 (1.5-24) 0.004
Pathologic differentiation
0.236WD-MD* 7 (14.3%) 6 ( 7.9%)
PD-SRC 42 (85.7%) 69 (90.8%)
Chronology
0.676Synchronous 34 (69.3%) 50 (65.8%)
Metachronous 15 (30.6%) 26 (34.2%)
Metastasis site
Peritoneum 38(77.6%) 66(86.8%) 0.175
Liver 6(12.2%) 10(13.2%) 0.881
Bone 5(10.2%) 11(14.4%) 0.723
Lung 2( 4.1%) 5( 6.6%) 0.704
Other 23(46.9%) 32(42.1%) 0.699
Extent of disease
0.028Limited to the ovary 7(14.3%) 2( 2.6%)
Beyond the ovary 42(85.7%) 74(97.4%)
R status
R0 resection 14 (28.6%)
R2 resection 35 (71.4%)
Serum CEA+ (ng/mL) 3.05 (0.01-36.3) 5.80 (0.01-121) 0.277
Normal 41 (83.7%) 56(73.7%)
0.083
Elevateda) 4 ( 8.2%) 15(19.7%)
Serum CA 19-9 (U/mL) 96.64 (0.1-1850) 484.5 (0.1-12100) 0.067
Normal 32 (65.3%) 30(39.5%)
0.009
Elevatedb) 14 (28.6%) 37(48.7%)
Serum CA 125 (U/mL) 74.1 (5.5-244) 187 (11-1555) 0.051
Normal 14 (28.6%) 11(14.5%)
0.159
Elevatedc) 14 (28.6%) 23(30.3%)
9Table 2. Clinical Characteristics of 91 Patients with Recurrent Krukenberg 
Tumor
Variables Arm A2#(n=58) Arm B2#(n=33) p value
Median age (yr) 43.9 (21-78) 45.9 (25-75) 0.372
≺50 41 (70.7%) 18 (54.5%)
0.121
≥50 17 (29.3%) 15 (45.5%)
Relapse free survival (mo) 24.3 (3-109) 27.8 (4-91) 0.435
Laterality
0.022Bilateral 42 (72.4%) 16 (48.5%)
Unilateral 16 (27.6%) 17 (51.5%)
Krukenberg tumor size (cm) 7.39 (3-18) 5.95 (1.9-15) 0.068
Pathologic differentiation
0.499WD-MD* 6 (10.3%) 5 (15.2%)
PD-SRC 52 (89.7%) 28 (84.8%)
AJCC stage
0.824stage I, II 26 (44.8%) 14 (42.4%)
stage III 32 (55.2%) 19 (57.6%)
Metastasis site
Peritoneum 45(77.6%) 26(78.8%) 0.894
Liver 4( 6.9%) 4(12.1%) 0.454
Bone 6(10.3%) 5(15.2%) 0.519
Lung 2( 3.4%) 0( 0%) 0.533
Other 33(56.9%) 13(39.4%) 0.108
Extent of diasease
0.250Limited to the ovary 7 (12.1%) 1 ( 3.0%)
Beyond the ovary 51 (87.9%) 32 (97.0%)
R status
R0 resection 27 (46.6%)
R2 resection 31 (53.4%)
Serum CEA+ (ng/mL) 2.79 (0.13-22.2) 332 (0.65-10410) 0.319
Normal 44 (75.9%) 24 (72.7%)
0.276
Elevateda) 8 (13.8%) 8 (24.2%)
Serum CA 19-9 (U/mL) 118.73 (0.1-2270) 1702 (0.1-20000) 0.097
Normal 38 (65.6%) 15 (45.5%)
0.035
Elevatedb) 14 (25.0%) 15 (45.5%)
Serum CA 125 (U/mL) 36.4 (4-241) 60..82 (5-227.8) 0.117
Normal 33 (56.9%) 10 (30.3%)
0.080
Elevatedc) 11 (19.0%) 9 (27.3%)
#Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus 
chemotherapy and arm B, chemotherapy alone.
*WD-MD, adenocarcinoma, well differentiated and adenocarcinoma, moderate differentiated; PD-SRC, 
adenocarcinoma, poorly differentiated and signet ring cell carcinoma.
+CEA, carcinoembryonic antigen; CA, cancer antigen. 
a)Serum CEA>5ng/mL, b)Serum CA-19-9>24U/mL, c)Serum CA 125>35U/mL. 
p-values from chi-square test except for krukenberg tumor size, median age at krukenberg tumor diagnosis, 
relapse free survival (Two-tailed Student’s t-test)
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2. Treatment outcome
The median OS of patients with initial stage IV gastric cancer was 12.0 months 
(95% CI, 9.7 to 14.3 months). The median OS of arm A1 and arm B1 was 18.0 
months (95% CI, 15.2 to 20.8 months) and 8.0 months (95% CI, 6.6 to 9.4 
months), respectively. Therefore, patients in the chemotherapy plus 
metastasectomy arm had a significantly better OS than patients in the 
chemotherapy arm (p < 0.001) (Fig. 1). The median OS of patients with recurrent 
Krukenberg tumors was 15.0 months (95% CI, 12.7 to 17.3 months). The median 
OS time of arm A2 and arm B2 was 19.0 months (95% CI, 14.4 to 23.6 months) 
and 9.0 months (95% CI, 6.2 to 11.8 months), respectively. Patients in the 
chemotherapy plus metastasectomy arm had a significantly better OS than 
patients in the chemotherapy alone arm (p=0.002) (Fig. 2). Upon univariate 
analysis of all patients, metastasectomy, signet-ring cell pathology, presence of 
peritoneal carcinomatosis, gastrectomy, and elevated serum levels of 
carcinoembryonic antigen (CEA; > 5 ng/mL), CA 19-9 (> 24 U/mL), and 
CA-125 (> 35 U/mL) were prognostic factors associated with survival. After 
adjusting for covariates in multivariate analysis, metastasectomy (hazard ratio 
[HR], 0.458; 95% CI, 0.287 to 0.732; p=0.001), signet-ring cell pathology (HR, 
1.583; 95% CI, 1.057 to 2.371; p=0.026), and presence of peritoneal 
carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were independent 
predictors of OS (Table 3). It was difficult to statistically analyze survival 
differences between patients in whom metastasis was limited to the ovary and 
those who have metastasis beyond the ovary because only 8% of patients showed 
metastasis limited to the ovary. Most of these patients were alive at the time of 
the study. A few patients who showed metastasis to other sites were subjected to 
additional surgery with oophorectomy, such as total hysterectomy and bowel 
resection. As shown in Fig. 3, the R0 resection group (n=41) had a significantly 
longer OS (HR, 0.405; 95% CI, 0.254 to 0.646; log-rank p < 0.001) than the R1, 
R2 resection group (n=66). The median OS was 30.0 months (95% CI, 24.0 to 
11
36.0) in the R0 resection group and 15.0 months (95% CI, 13.6 to 16.4) in the R1, 
R2 resection group. Oophorectomy was found to still be beneficial when other 
unresectable metastasis were present, for both metastatic and recurrent disease. 
Analysis of all cases except single ovarian metastasis revealed that the median 
OS time of arm A1 and arm B1 was 16.0 months (95% CI, 13.7 to 18.3 months) 
and 8.0 months (95% CI, 6.6 to 9.4 months; p < 0.001), respectively. 
Additionally, the median OS time of arm A2 and arm B2 was 16.0 months (95% 
CI, 12.5 to 19.5 months) and 8.0 months (95% CI, 5.8 to 10.2 months; p=0.039), 
respectively. The frequencies and response rates of chemotherapy regi mens 
initially used after ovarian metastasis diagnosis were also analyzed (Table 4). 
Overall, 111 patients were treated with chemotherapy for ovarian metastasis, 
with platinum (n=43), taxane (n=26), and irinotecan (n=8) chemotherapy 
regimens being the most frequently used. Chemotherapy regimens did not differ 
significantly between arms A and B (p=0.535). Patients who received 
chemotherapy for ovarian metastasis were evaluated using the Response 
Evaluation Criteria in Solid Tumors ver. 1.1. Tumor assessment included 
measurable metastatic ovarian lesions and not overall gastric cancer lesions. The 
response rates for the chemotherapy regimens were as follows: platinum, 26%; 
irinotecan, 25%; and taxane, 12%.
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Fig 1. Kaplan-Meier overall survival based on treatment Arm in initial stage IV 
gastric cancer
13
Fig 2. Kaplan-Meier overall survival based on treatment Arm with recurred 
krukenberg tumor
Table 3. Univariate and Multivariate Analysis Showing Factors Associated with 
Overall Survival in 216 Patients
Variable
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Metastasectomy 0.404 (0.302-0.539) <0.001 0.458 (0.287-0.732) 0.001
Age (≥50yr) 1.065 (0.769-1.477) 0.704
Metachronous disease 0.870 (0.587-1.289) 0.487
Unilateral ovarian metastases 1.097 (0.809-1.487) 0.552
Size of krukenberg tumor(<5cm) 0.749 (0.547-1.024) 0.070
Signet-ring cells 0.642 (0.479-0.859) 0.003 1.583 (1.057-2.371) 0.026
Peritoneal carcinomatosis 3.034 (1.990-4.625) <0.001 3.081 (1.610-5.895) 0.001
Gastrectomy 2.022 (1.507-2.712) <0.001 1.293 (0.787-2.124) 0.311
Relapse free survival (≥12month) 1.433 (0.958-2.144) 0.080
CEA 1.434 (1.061-1.938) 0.052
CA 19-9 1.614 (1.193-2.182) 0.002 0.683 (0.447-1.042) 0.077
CA 125 2.091 (1.420-3.078) <0.001 0.653 (0.421-1.014) 0.057
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Fig 3. Kaplan-Meier overall survival based on curative resection of krukenberg 
tumor in stomach cancer
Table 4. The frequencies and response rates of chemotherapy regimens initially 
used after ovarian metastasis diagnosis
Arm A1 Arm A2 Arm B1 Arm B2 Total
n %RRd) n %RR n %RR n %RR n %RR
Platinuma) 8 25 1 0 21 14 13 46 43 26
Irinotecanb) 0 0 0 0 4 25 4 25 8 25
Taxanec) 4 0 2 0 17 18 3 0 26 12
Total 12 17 3 0 42 17 20 35 77 21
a) Platinum : Cisplatin+TS-1, Cisplatin+Capecitabine (XP), Cisplatin+5-FU (FP), Oxaliplatin+Capecitabine 
(XELOX), Oxaliplatin+5-FU/LV (FOLFOX), Oxaliplatin+TS-1 (SOX).
b) Irinotecan : Irinotecan mono, Irinotecan+TS-1, Irinotecan+5-FU/LV(FOLFIRI)
c) Taxane : Paclitaxel mono, Paclitaxel+5-FU/LV, Paclitaxel+TS-1, Docetaxel mono, Docetaxel+5-FU/LV, 
Docetaxel+TS-1, Docetaxel+Capecitabine.
d) RR : response rate (CR or PR patients / total patients.).
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IV. DISCUSSION
Most patients diagnosed with Krukenberg tumor of gastric origin have poor 
prognosis. Many studies have shown that the median survival after Krukenberg 
tumor diagnosis is 7-11 months13. In the past, symptomatic patients received 
palliative operation for symptom relief. Recently, the development of diagnostic 
tools has increased early detection of Krukenberg tumors and their curative 
resectability. Nevertheless, the optimal treatment strategy for Krukenberg tumors 
has not been established. Our study showed that patients with Krukenberg tumor 
of gastric origin who underwent both chemotherapy plus metastasectomy had 
longer OS than those who underwent chemotherapy alone, regardless of stage. 
The difference in OS was actually underestimated because the OS in arms A2 
and B2 was determined from the date of recurrent Krukenberg tumor diagnosis 
and not the date of the initial gastric cancer diagnosis. Despite the small 
proportion of R0 resections, a prolonged OS was observed in the chemotherapy 
plus metastasectomy arm. In our study, one patient in arm A1 survived more than 
9 years after the initial diagnosis of gastric cancer, while one patient in arm A2 
survived more than 7.5 years after resection of metachronous Krukenberg tumor. 
Some studies have reported the survival benefit of metastasectomy for 
Krukenberg tumor; however, most of these included a small number of patients 
(approximately 50 patients) and Krukenberg tumors of different origins, 
including gastric, colon, and breast cancers14. Many reports have suggested that 
metastasectomy provides a better survival benefit for Krukenberg tumors of CRC 
origin15-17. Among studies of the survival benefit of metastasectomy for 
Krukenberg tumor, ours is the largest conducted to date and the only one that 
investigated Krukenberg tumors of gastric cancer origin exclusively. A few 
studies have demonstrated that metastasectomy of metachronous recurrent 
Krukenberg tumor of gastric origin provided longer OS18-20. Based on our results, 
metastasectomy should be performed in stage IV gastric cancer patients 
diagnosed synchronously or metachronously with Krukenberg tumor. Our 
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recommendation is consistent with those of previous reports21,22. In the present 
study, the prognostic factors associated with survival in patients with Krukenberg 
tumor of gastric origin were analyzed. Metastasectomy, signet-ring cell 
pathology, and peritoneal carcinomatosis were identified as significant prognostic 
factors. Several studies have also shown that metastasectomy is a prognostic 
factor for better OS in patients with Krukenberg tumors18,19. In the present study, 
absence of peritoneal carcinomatosis was associated with better prognosis, which 
is consistent with the results of a previous study that showed limited disease 
extent as a prognostic factor2. Complete resection is easily achieved when the 
extent of disease is limited; therefore, active Krukenberg tumor metastasectomy 
should be conducted in patients who are not expected to have residual disease 
after operation. Adenocarcinomas composed of signet ring cells tend to 
metastasize to the ovaries more frequently than adenocarcinomas of other 
histologic types23. Signet ring cell features have not been well established as a 
prognostic factor for Krukenberg tumors; however, in the present study, they
were a poor prognostic factor for Krukenberg tumors of gastric cancer origin. 
Published studies of the role of chemotherapy in the treatment of Krukenberg 
tumors have included only small patient numbers or case reports. In the present 
study, response rates to chemotherapy regimens were analyzed in 111 patients 
diagnosed with Krukenberg tumor, and response rates ranged from 12% to 26%. 
In most of our cases, Krukenberg tumor was diagnosed during later stages of 
gastric cancer progression. Therefore, at the time of Krukenberg tumor diagnosis, 
patients have already received standard first-line chemotherapy for advanced or 
metastatic gastric cancer. In our experience, ovarian metastases show less 
chemotherapy responsiveness than other sites of metastasis. Early detection of 
ovarian metastases is important to successful treatment. In the present study, 
serum CEA, CA 19-9, and CA-125 level were not useful predictors of 
Krukenberg tumor. Despite continual efforts to develop a practical biomarker that 
can predict relapse or metastasis of ovary metastasis with gastric cancer, no 
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clinical tests have been established24. Clinical heterogeneity is most likely due to 
the diverse molecular profile of gastric cancer. Thus, identifying diversity in the 
molecular profile of gastric cancer that governs the clinical behavior of tumors 
could lead to new and more effective clinical strategies. Recent studies of gastric 
cancer have identified genes that differ according to histologic factors and age, as 
well as those useful for gastric cancer prognosis prediction24. We will continue to 
identify genes and develop a practical biomarker in future studies. It should be 
noted that several factors may have affected the decision of surgery for treatment 
of the patients evaluated in the present study, including the extent of metastasis, 
possibility of curative surgery, surgeon’s opinion, etc. Additionally, the 
difference in the chemotherapy regimen between arm A and arm B may have 
influenced patient survival or toxicity. CT was used to identify patients who 
would benefit from the curative resection of Krukenberg tumors. Although 
imaging modalities, including CT scanning, have been developed to detect 
intraperitoneal metastasis, CT has been shown to only have a 50% accuracy for 
detecting intraperitoneal metastatic cancers25. Therefore, peritoneal 
carcinomatosis is difficult to diagnosis by CT scan. Laparoscopic examination 
has shown better accuracy in detecting peritoneal carcinomatosis; however, this 
procedure is invasive and can result in complications.
V. CONCLUSION
In conclusion, we demonstrated that metastasectomy was associated with 
longer survival in patients with Krukenberg tumors in gastric cancer. Therefore, 
metastasectomy should be performed in stage IV gastric cancer patients 
diagnosed synchronously or metachronously with Krukenberg tumor. Our data 
also suggest that metastasectomy plus chemotherapy may play a role in the 
treatment of Krukenberg tumors of gastric origin. Furthermore, we found that 
metastasectomy, signet ring cells, and peritoneal carcinomatosis were prognostic 
factors for Krukenberg tumors. Future prospective randomized trials are needed 
18
to confirm our findings and will be important in establishing standard treatment 
guidelines for patients with Krukenberg tumor in metastatic gastric cancer.
19
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ABSTRACT(IN KOREAN)
Krukenberg 종양을 가진 진행성 위암에서 수술과 항암치료
병합요법과 고식적 항암치료 단독요법의 비교
<지도교수 조 재 용>
연세대학교 대학원 의학과
조 장 호
본 연구는 krukenberg 종양을 가진 위암 환자의 치료에서, 
전이병변 절제와 항암치료의 병행요법이 항암치료 단독요법보다
생존 이득이 있음을 확인하고 생존에 대한 예후 인자를
확인하기 위해 수행되었다. 위암에서 krukenberg 종양을 가진
216명의 환자에서 임상 데이터를 수집하였다. 환자들은 치료
방법에 따라 두 군으로 분류하였다. A군은 전이병변 절제와
항암치료 병행요법, B군은 항암치료 단독요법만 시행한
환자들이다. 전체 생존기간은 처음 위암4기로 진단받은
환자들에서 A군이 B군보다 통계적으로 유의하게 증가하였고
(18개월 vs 8개월; p<0.001), 위암수술 이후 재발하여 생긴
krukenberg종양을 가진 환자들에서도 증가하였다. (19개월 vs 
9개월; p=0.002). 전이병변 절제 (암 발생 위험율, 0.458; 95% 
신뢰구간, 0.287 to 0.732; p=0.001), 반지 세포 병리 (암 발생
위험율, 1.583; 95% 신뢰구간, 1.057 to 2.371; p=0.026), 그리고 복막
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암종증 (암 발생 위험율, 3.081; 95% 신뢰구간, 1.610 to 5.895; 
p=0.001) 들이 생존을 위한 중요한 예후 인자들이었다. 
Krukenberg 종양을 가진 위암 환자에서 전이병변 절제와
항암치료 병행요법이 항암요법 단독요법과 비교하였을 때
우월한 전체 생존기간을 가진다. 위암 병기에 상관없이
생존기간 우월함은 모든 환자들에 적용된다. 전이병변 절제, 
반지 세포 병리, 복막 암종증은 생존에 대한 예후 인자들이었다. 
Krukenberg 종양을 가진 위암 환자에서 최적의 치료 전략을
확인하기 위해 추후 전향성 무작위 임상시험들이 필요하겠다.
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